Actively Recruiting
Prospective Cohort for the sEcoNDary Prevention of Ventricular Tachycardia in Patients With Cardiomyopathies (END-VT) Study
Led by Nova Scotia Health Authority · Updated on 2024-07-16
2454
Participants Needed
3
Research Sites
52 weeks
Total Duration
On this page
Sponsors
N
Nova Scotia Health Authority
Lead Sponsor
M
Maritime Heart Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ventricular tachycardia (VT) is a serious heart rhythm problem that can lead to sudden cardiac death and other severe complications. This study focuses on patients with cardiomyopathy who have experienced VT, aiming to find the best treatment approaches to improve long-term outcomes. Researchers will also examine how VT affects patients in real-world settings, including treatment safety, effectiveness, adherence to guidelines, and cost-effectiveness. The study follows patients with ischemic and non-ischemic cardiomyopathy from their first VT event for at least three years or until death. Researchers will collect data remotely from implantable cardiac defibrillators (ICDs) and review these events carefully without knowing the patient's treatment or center. The goal is to identify the most effective treatment sequences to maximize event-free survival. Participants will be monitored through ICD remote tracking and clinical evaluations over time. The main outcome is to determine the best treatment plan for each patient over five years. The study also looks at how treatments are used in practice and differences in outcomes between men and women. Participants will be followed closely for safety and treatment results throughout the study period.
CONDITIONS
Brief Title
END - VT Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented sustained ventricular arrhythmia lasting more than 30 seconds as confirmed by ECG or device recordings
- First (new) diagnosis of ventricular tachycardia
- Presence of or planned implantable cardiac defibrillator (ICD) during initial hospitalization
- Diagnosis of cardiomyopathy including ischemic, hypertrophic, dilated, restrictive, arrhythmogenic, or other scar-related types
- Planned follow-up at an ICD clinic
- Age over 18 years old
You will not qualify if you...
- Ventricular tachycardia caused by a reversible condition
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 3 years or until death
Participants with cardiomyopathy-related ventricular tachycardia are monitored using implantable cardiac defibrillator (ICD) remote monitoring devices to capture VT events and clinical outcomes.
Follow-up visits at ICD clinics as scheduled by routine care
Trial Site Locations
Total: 3 locations
1
Providence Health Care Society
Vancouver, British Columbia, Canada
Actively Recruiting
2
QEII Health Science Centre
Halifax, Nova Scotia, Canada, B3H3A7
Actively Recruiting
3
Montreal Heart Institute,
Montreal, Quebec, Canada, H1T 1C8
Actively Recruiting
Research Team
J
John L Sapp, MD, FRCPC
S
Suzanne E Greeley, BSCN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here